Pharmaxis Ltd (PXS.AX) Announces Major Milestone: Positive Bronchitol Opinion for Europe  
10/25/2011 9:54:22 AM

SYDNEY--(BUSINESS WIRE)--Pharmaceutical company Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe “for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care.”